| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| May 5, 2026 | ±1.8% | -1.3% | over-priced |
| November 4, 2025 | ±2.0% | -1.0% | over-priced |
| August 5, 2025 | ±2.3% | -20.6% | under-priced |
| May 6, 2025 | ±2.4% | -10.0% | under-priced |
| November 5, 2024 | ±1.9% | +5.7% | under-priced |
| August 2, 2024 | ±2.1% | -2.2% | under-priced |
| May 7, 2024 | ±2.0% | +1.9% | over-priced |
| November 7, 2023 | ±2.3% | -1.9% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $4.02 | $3.0B | $1.0B |
| Q4 FY2025 | $4.64 | $3.2B | $1.2B |
| Q3 FY2025 | $4.20 | $3.1B | $1.1B |
| Q2 FY2025 | $3.99 | $3.0B | $1.0B |
Vertex Pharmaceuticals Inc (VRTX) reports in 97 days, with the next report estimated for September 18, 2026. Across the last 8 reports, options priced an average ±2.1% earnings move while the stock actually moved 5.6% on average — the market has been roughly fair on VRTX's earnings risk. Fundamentals into the print: EPS up 61.4% year-over-year, revenue up 7.8%. QuantLogix's live 5-factor engine currently reads VRTX as a buy at 63/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →